PlantArcBio Corn Trial Reports Yield Gains Under Drought

PlantArcBio has reported large yield gains from experimental corn carrying its lead drought tolerance genes in the company’s first open field trial. The 2026 study in Israel covered 200 plots and tested both inbred and hybrid material under standard irrigation and severe sustained drought.

The Israeli agricultural biotechnology company discovered the candidate genes through its Direct In Plant platform, which screens large gene libraries in living plants exposed to stress. The approach is designed to identify traits that remain useful beyond laboratory screening, although field performance still has to be confirmed across locations and seasons.

The trial ran from April through August with multiple replications. PlantArcBio said transformed plants showed more vigorous growth and more uniform flowering than untransformed controls, including under the drought treatment.

According to the company, total cob weight per plot more than tripled relative to controls under irrigation, with a comparable gain under drought. Across three lead gene events in advanced hybrid corn, kernel yield exceeded the control in both water regimes and, in some cases, more than doubled under drought.

Those figures are promising but preliminary. They come from a company disclosed trial at one location, involve experimental transformed material, and have not yet established performance in commercial hybrids across different soils, climates or management systems.

The flowering response matters because drought can reduce yield long before harvest by disrupting pollination and grain formation. A trait that keeps reproductive development on schedule could therefore contribute value even when its visible effect is not limited to plant survival.

PlantArcBio says it is seeking seed company and breeding programme partners to integrate the genes into elite germplasm. The next evidence needed is multilocation testing, stable performance across genetic backgrounds, agronomic quality data and the regulatory work required for each target market.

For the seed industry, the trial is best read as an early validation signal rather than proof of a market ready product. The commercial opportunity will depend on whether the reported gains persist through independent, replicated development at the scale and consistency required by growers.